Drugs / MSC
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT02379442 | Feb 2015 → Dec 2017 | acute graft versus host disease | National Heart, Lung, and Blood Institute (NHLBI) | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MSC | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02379442 ↗ |
| Known as | BMSC | “bone marrow-derived mesenchymal stem cell (BMSC) infusions” NCT02379442 ↗ |
| Modality | Cell therapy | “bone marrow-derived mesenchymal stem cell (BMSC) infusions” NCT02379442 ↗ |
| Route | Intravenous | “BMSC will be given through a small plastic tube in an arm vein or through an IV catheter.” NCT02379442 ↗ |